Pacific Biosciences of California, Inc. (PACB) Guidance & Earnings Results
On 2026-08-05 Pacific Biosciences of California, Inc. lowered guidance: "FY2026 revenue guidance $155-165M (vs prior implied ~$160-170M based on Q1 run-rate); restructuring expected to reduce annualized operating expenses by $30-40M by end of…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PACBPacific Biosciences of California, Inc.Follow PACB — free
—
Price chart with a free account
- Market cap
- 655.9M
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 5 Aug 26 | Lowered | FY2026 revenue guidance $155-165M (vs prior implied ~$160-170M based on Q1 run-rate); restructuring expected to reduce annualized operating expenses by $30-40M by end of 2027 · full year |
| 7 May 26 | Reaffirmed | FY26 revenue $165-175M · full year |
Pacific Biosciences of California, Inc. — questions
- What guidance did Pacific Biosciences of California, Inc. give?
- On 2026-08-05: "FY2026 revenue guidance $155-165M (vs prior implied ~$160-170M based on Q1 run-rate); restructuring expected to reduce annualized operating expenses by $30-40M by end of 2027"
- When does Pacific Biosciences of California, Inc. report earnings?
- Pacific Biosciences of California, Inc.'s next earnings report is expected on 2026-11-04.
Every figure on this page comes from Pacific Biosciences of California, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.